Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.


What's New

 

The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.

Toyama Chemical Co., Ltd. Initiates Phase 2 Clinical Trial in the US of its Anti-influenza Drug Candidate T-705
February 15, 2010

Toyama Chemical Co., Ltd. (Headquarters: Tokyo, Japan; President: Masuji Sugata, “Toyama Chemical”), a subsidiary of FUJIFILM Holdings Corporation, announced today that it has started Phase 2 clinical trial in the US of its novel anti-influenza drug T-705 (generic name: favipiravir).

In the US, clinical trials have been conducted since March 2007, and in the current Phase 2 clinical trial, Toyama Chemical will conduct a randomized, double-blind study evaluating the efficacy and safety of high and low doses of T-705 compared to placebo in patients with influenza A or B.

T-705 is an RNA polymerase inhibitor with a novel mechanism of action. It has already shown signs of efficacy in another Phase 2 clinical trial conducted in Japan. Currently, a Phase 3 clinical trial in Japanese patients with influenza including H1N1 has been ongoing since October 29, 2009.

T-705 could become extremely valuable in providing an alternative influenza therapy, especially in terms of fighting emerging resistant viral strains. This is due to its novel mechanism of action which involves direct inhibition of viral RNA reproduction, while existing anti-influenza drugs only prevent the spread of infection to adjacent cells by inhibiting viral release from host cells.

Toyama Chemical specializes in pharmaceutical research and development, and strives to “contribute to the further development of global health care through new drug development”.

Footer starts here.

Pages ends here.
Move to top of the page.
=